Drug-release type gel for treating fundus macular degeneration and preparation method thereof

A technology of gel and drug release, applied in the field of medicine, can solve the problems of patients suffering, difficult operation, bleeding at the injection site, etc., and achieve the effects of saving medical expenses, avoiding pain, and high safety

Inactive Publication Date: 2019-07-05
SHANGHAI TONGREN HOSPITAL
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The two drugs have the following disadvantages in the way of administration: 1. Need to puncture the eyeball to achieve intravitreal injection, which is difficult to operate and requires very high qualification requirements for surgeons; 2. The price of drugs and s

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Step 1: Dissolving the inducing compound dexamethasone in a mixture of pure water and dimethyl sulfoxide, the volume ratio of pure water and dimethyl sulfoxide is 1:1, and the mass fraction of dexamethasone is 0.1% ~0.3% solution.

[0032] Step 2: Dissolve 1 mL of the anti-VEGF drug (anti-angiogenic drug) Conbercept (10 mg / mL) in 1 mL of the solution obtained in Step 1.

[0033] Step 3: Dissolving polyvinyl alcohol 1788 in pure water to prepare a solution with a mass fraction of polyvinyl alcohol 1788 of 0.1% to 0.5%. In this step, polyethylene glycol can also be used to replace polyvinyl alcohol. Polyvinyl alcohol and polyethylene glycol are common components of eye drops. At present, polyvinyl alcohol can be used as a lubricant to prevent or treat eye dryness, foreign body sensation, eye fatigue and other irritation symptoms or to improve eye dryness. Polyethylene glycol Alcohol is mainly used for the temporary relief of burning and stinging symptoms due to dry eyes....

Embodiment 2

[0042] The inducing compound in Step 1 of Example 1 is replaced by dexamethasone / cortisone with a mass ratio of 1:1, and the Conbercept (10mg / mL) in Step 2 of Example 1 is replaced by Raizumab monoclonal antibody (10mg / mL), and the rest of the steps are the same as in the first implementation. The obtained drug-releasing gel for the treatment of fundus and macula can realize sustained drug release after bonding with the cornea. The effect of visual acuity improvement.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses drug-release type gel for treating fundus macular degeneration and a preparation method thereof. The drug-release type gel comprises an anti-angiogenesis drug, an inducing compound and gel and is characterized in that the inducing compound is used for increasing the permeation of the drug, and the gel attaches to the cornea during use and serves as the carrier of the drug;the anti-angiogenesis drug is selected from Lucentis or Compaq; the inducing compound is selected from optional one of dexamethasone, prednisone and cortisone or the combination of two of dexamethasone, prednisone and cortisone; the gel serving as the drug carrier is prepared by preparing a solution containing polydopamine and methacrylate gelatin, adding crosslinking agent N,N-methylene bisacrylamide and initiator potassium peroxydisulfate into the solution, and performing fixed-die forming to obtain the gel which does not contain the drug. The drug-release type gel has the advantages that non-invasive drug delivery is adopted, sustained drug release is achieved after the gel attaches to the cornea, and the anti-VEGF drug is allowed to act on the vitreous body by utilizing the permeability of the inducing compound.

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to a medicine slow-release gel, in particular to a medicine-release gel for treating fundus and macula and a preparation method thereof. Background technique [0002] Age-related macular degeneration, also known as age-related macular degeneration (AMD). Exudation, degeneration, or subretinal hemorrhage in the macula of the affected eye. The disease mostly occurs in middle-aged and elderly people, and its prevalence is positively correlated with age. It is currently the main cause of blindness in people over 50 years old. With the aging of the Chinese population, the disease has a clear upward trend. In terms of clinical manifestations, AMD is divided into dry (atrophic) AMD and wet AMD (neovascular). Among them, dry AMD does not cause serious visual impairment in the early stage of the lesion, but once neovascularization occurs in wet AMD, there will be obvious weakening of visio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/06A61K45/06A61K47/42A61P27/02
CPCA61K9/06A61K9/0004A61K9/0048A61K45/06A61K47/42A61P27/02
Inventor 陈诚朱志刚陈功赵雪伶邵侃王璐
Owner SHANGHAI TONGREN HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap